Skip to main content
Premium Trial:

Request an Annual Quote

Genset, Pharmacia and Upjohn Sign Two-Year Collaboration Deal

Premium

PARIS--Genset, a genomics company here, struck a two-year research agreement with Pharmacia and Upjohn in which the companies will use Genset's pharmacogenomics technology to identify genetic markers among patients involved in clinical studies of a Pharmacia and Upjohn compound. Using a proprietary high-resolution biallelic marker map, Genset said it will analyze well characterized data and samples of responders and nonresponders from selected Pharmacia and Upjohn clinical studies to maximize the practical medical and pharmaceutical applications of its genomics discoveries. Genset will receive research fees, research and clinical milestone payments, and royalty payments on future sales of the collaborative compound that would make use of the pharmacogenomics discoveries.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.